P

Pfizer

Makes cancer drugs, vaccines and other medicines

Valuation Director/Team Lead - Valuation Center of Excellence

Full-TimeUpdated on 10/14/2026Deadline 10/29/26
$176.6k - $294.3k/yr+ 20% target bonus + Share-based long-term incentive program
Senior, Expert
Bachelor's, Master's
New York, NY, USA
HybridOn-site 2.5 days per week required.
Finance & BankingCorporate Finance & FP&A
No H1B Sponsorship

About the job

Requirements
  • A Bachelor of Arts or Bachelor of Science degree in life science, finance, engineering, or a quantitative discipline.
  • At least 8 years of experience in management consulting, investment banking, equity research, corporate or research and development finance, portfolio management, or decision analysis, including at least 3 years building pharmaceutical asset valuations.
  • Demonstrated expertise in expected cash flow modeling and economic value measures, including eNPV and eIRR, and in decision analysis techniques such as decision trees, Monte Carlo simulation, multi-attribute analysis, and value of information.
  • Expert command of pharmaceutical research and development economics, including phase transition probabilities, development cost and timeline drivers, indication sequencing, exclusivity, and loss of exclusivity.
  • Demonstrated experience setting analytical standards and enforcing them across teams the role does not control.
  • Hands-on tool-building capability, including advanced Excel plus at least one of Python, R, or equivalent, and practical use of artificial intelligence or large language model tools within an analytical workflow, such as Claude, Gemini, or Copilot.
  • Experience managing, mentoring, or formally coaching junior colleagues.
  • Excellent Microsoft Excel and PowerPoint skills.
  • Candidates must be authorized to be employed in the United States by any employer and have permanent work authorization in the United States.
Responsibilities
  • Set and execute the roadmap for artificial-intelligence-assisted valuation and decision-support workflows, defining what work should be automated, augmented, or retained as human judgment.
  • Design reusable prompts, agents, and workflows across approved generative artificial intelligence platforms to accelerate model development, assumption retrieval, scenario generation, quality checks, and executive deliverables.
  • Identify and automate recurring analytical tasks; evaluate emerging artificial intelligence technologies and recommend adoption strategies with Enterprise Portfolio Management, Digital, and other business partners.
  • Establish artificial intelligence governance, validation, traceability, and human-review controls so machine-assisted outputs are transparent, reproducible, and fit for governance use.
  • Partner with Therapeutic Area Decision Analysis Directors to frame and pressure-test business questions, decision criteria, options, and key uncertainties before modeling begins.
  • Apply Decision Quality methods, including decision hierarchies, strategy tables, decision trees, scenario planning, and value of information, to structure complex choices.
  • Translate development strategies and trade-offs into artificial-intelligence-enabled analytical frameworks, probabilistic analyses, sensitivities, and clear value drivers at the asset and indication level.
  • Provide objective challenge to Commercial, Clinical, Regulatory, and Finance assumptions and convert complex findings into concise, actionable recommendations.
  • Flex and lead decision analysis projects within any therapeutic area when there are potential capacity issues or peak project volume.
  • Together with the Head of PDA Decision Analysis and Therapeutic Area Decision Analysis Directors, own valuation metrics used to inform consequential portfolio prioritization and multi-billion-dollar investment go/no-go decisions at the Portfolio Management Team.
  • Own PDA’s Common Analytical Practices, including cash flow architecture, risk adjustment, discount rates, eNPV, eIRR, probability of technical and regulatory success benchmarks, and standards for approved deviations.
  • Serve as final quality reviewer for internal pipeline valuations, ensuring consistent assumptions, cross-asset comparability, transparent documentation, and audit-ready outputs before governance review.
  • Maintain standardized model templates, version control, reusable analytical frameworks, and an artificial-intelligence-enabled knowledge repository on the Common Analytic Platform.
  • Align input and reconciliation standards with Enterprise Portfolio Management, Finance, Commercial, Business Assessment, Research and Development, and Business Development across internal and external opportunities.
  • Lead the Valuation Center of Excellence team, including performance management, work assignment, intake, prioritization, and capacity balancing across therapeutic areas.
  • Build team capability in valuation, decision analysis, therapeutic-area knowledge, executive storytelling, and effective use of generative artificial intelligence for analytical decision support.
  • Coach and develop colleagues through clear career paths, stretch assignments, asset-team exposure, peer review, and post-decision learning.
  • Establish a culture of analytical excellence, continuous improvement, knowledge sharing, and accountable delivery.
  • Integrate asset- and indication-level valuations across Research and Development, Commercial, Finance, and Enterprise Portfolio Management to support operating plans, long-range forecasts, and portfolio prioritization.
  • Create executive-ready presentations, business cases, dashboards, and briefing materials that clearly communicate value drivers, scenarios, risks, and recommendations.
  • Represent asset- and indication-level valuation methodology and findings at Category, Portfolio Management Team, and other governance forums, enabling transparent, data-driven investment decisions.
Desired Qualifications
  • An advanced degree in business, decision analysis, engineering, medicine or science, or a related quantitative field.
  • Experience supporting business development, licensing, or mergers and acquisitions valuation alongside internal pipeline work.
  • Experience deploying artificial intelligence or large language model tooling in a regulated or controls-sensitive environment, including validation and audit considerations.
  • Experience in a center of excellence, shared service, or other capability-based analytics team.
  • Experience and expertise in portfolio management and portfolio analytics systems.
  • Breadth of diverse leadership experiences and capabilities, including influencing and collaborating with peers, developing and coaching others, and overseeing and guiding colleagues’ work to achieve meaningful outcomes and create business impact.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.

Yahoo Finance
Oct 12th, 2026
UPS, Pfizer, Kraft Heinz and Ford dividends at risk as payouts outstrip earnings

Four blue chip companies, UPS, Pfizer, Kraft Heinz, and Ford, may struggle to sustain their dividends, according to an analysis of their earnings, cash flow, and debt. UPS yields 7.02% and pays out about 121% of its GAAP earnings. Pfizer yields 6.10%, with a GAAP payout ratio of about 226%; its 2025 free cash flow of $9.076 billion fell short of $9.771 billion in dividends. Kraft Heinz yields 6.82%, but its trailing GAAP earnings per share are −$2.88 after $7.4 billion in impairments. Ford yields 4.98% after an $8.162 billion loss in 2025, and its debt-to-equity ratio is 4.66. All four companies say their payouts are safe, and each points to adjusted earnings guidance that covers the dividend.